Abstract
Decision tools are becoming critical to medical decision-making, due to the complexity of available information that outstrips the capacity to synthesize it without assistance. Tools such as decision trees, algorithms and nomograms may be used to facilitate treatment decisions, evaluating endpoints such as survival and toxicity. Incorporation of biologic and molecular data is increasingly being used in decision-making in cancer, for example in selecting systemic therapies, and will soon be expanded to include decisions about radiotherapy and surgery. Health technology is an integral part of decision tools development, allowing rapid access to data and distributed access to users. However, the limitations in the development and use of decision tools must be recognized, and solutions developed to facilitate their widespread implementation and improve healthcare outcomes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alper BS, Hand JA, Elliott SG et al (2004) How much effort is needed to keep up with the literature relevant for primary care? J Med Libr Assoc 92:429–437
Bast RC Jr, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878
Cronin M, Sangli C, Liu ML et al (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53:1084–1091
Davenport TH, Glaser J (2002) Just-in-time delivery comes to knowledge management. Harv Bus Rev 80:107–11
Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870
Gage BF, van Walraven C, Pearce L et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292
Heemsbergen WD, Peeters ST, Koper PC et al (2006) Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 66:3–10
Hunink M, Glasziou P (2011) Decision making in health and medicine. Cambridge University Press, New York
Italiano A (2011) Prognostic or predictive? It’s time to get back to definitions! J Clin Oncol 29:4718 (author reply 4718–9)
Kanes AC, Healey JS, Cairns JA et al (2012) Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 28:125–136
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Kattan MW (2007) Outcome prediction in cancer. Elsevier, Oxford
Lau SK, Boutros PC, Pintilie M et al (2007) Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25:5562–5569
Lenfant C (2003) Shattuck lecture—clinical research to clinical practice—lost in translation? N Engl J Med 349:868–874
Memorial Sloan Kettering Cancer Centre (2013) Prostate cancer nomograms. http://nomograms.mskcc.org/Prostate/PreTreatment.aspx. Accessed 1 Mar 2013
Miot J, Wagner M, Khoury H et al (2012) Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. Cost Eff Resour Alloc 10:2
Olivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725
Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100
Rothman KJ (2002) Epidemiology: an introduction. Oxford University Press, New York
Shakespeare TP, Gebski VJ, Veness MJ et al (2001) Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet 357:1349–1353
Skanes AC, Healey JS, Cairns JA et al (2012) Focused 2012 update of the Canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 28:125–136
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181
Trotti A, Pajak TF, Gwede CK et al (2007) TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613–624
Yom SS, Liao Z, Liu HH et al (2007) Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68:94–102
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Giuliani, M.E., Hope, A.J., Fyles, A. (2013). Introduction to Decision Tools. In: Nieder, C., Gaspar, L. (eds) Decision Tools for Radiation Oncology. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2013_843
Download citation
DOI: https://doi.org/10.1007/174_2013_843
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-37101-1
Online ISBN: 978-3-642-37102-8
eBook Packages: MedicineMedicine (R0)